Anti-PFKFB1 Recombinant Antibody Products

Loading...

Anti-PFKFB1 Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.

Creative Biolabs is a leading provider of premium recombinant antibodies, including highly specific PFKFB1-targeting solutions, designed to propel biomedical research forward. Leveraging advanced proprietary technologies, we deliver rigorously validated reagents that consistently meet stringent quality benchmarks, empowering scientists with reliable tools for groundbreaking discoveries. Our comprehensive portfolio of recombinant biologics combines innovation with affordability, ensuring researchers have access to cutting-edge resources without compromising performance. Beyond product excellence, we offer unparalleled expert guidance throughout experimental workflows, from initial design to data interpretation. Partnering with us means securing both state-of-the-art research solutions and committed scientific collaboration tailored to accelerate your project's success.

PFKFB1: A Key Metabolic Regulator in Cancer Cardiovascular Disease and Neurodegeneration

PFKFB1 plays a pivotal role in metabolic regulation, particularly in glycolysis, making it a compelling therapeutic target for various diseases. Dysregulation of this enzyme contributes to pathological conditions such as cancer, where its overexpression enhances glycolytic flux, fueling tumor proliferation and metastasis. In cardiovascular diseases, altered activity disrupts endothelial cell function, exacerbating atherosclerosis and ischemia-reperfusion injury. Additionally, its involvement in insulin signaling pathways links it to metabolic disorders like diabetes, where impaired function leads to aberrant glucose metabolism and insulin resistance. Neurodegenerative conditions, including Alzheimer’s disease, are also influenced by its activity, as disrupted energy metabolism in neurons accelerates cognitive decline. Furthermore, inflammatory diseases such as rheumatoid arthritis exhibit elevated levels, promoting pro-inflammatory cytokine production and tissue damage. Given its broad impact across multiple pathological processes, modulating this target presents a promising strategy for developing novel treatments, particularly in diseases driven by metabolic and inflammatory dysregulation. Therapeutic interventions aimed at restoring its normal function could offer significant clinical benefits, addressing unmet medical needs in oncology, cardiometabolic disorders, and neurodegeneration.

Alternative Names

Complement F6PK; HL2K; PFRX

Background

This gene encodes a member of the family of bifunctional 6-phosphofructo-2-kinase:fructose-2,6-biphosphatase enzymes. The enzyme forms a homodimer that catalyzes both the synthesis and degradation of fructose-2,6-biphosphate using independent catalytic domains. Fructose-2,6-biphosphate is an activator of the glycolysis pathway and an inhibitor of the gluconeogenesis pathway. Consequently, regulating fructose-2,6-biphosphate levels through the activity of this enzyme is thought to regulate glucose homeostasis. Multiple alternatively spliced transcript variants have been found for this gene.

Anti-PFKFB1 rAb Products

To accelerate scientific breakthroughs, we provide premium-grade recombinant antibodies targeting PFKFB1, delivering exceptional performance, cost-effective solutions, and comprehensive expert guidance to support researchers throughout their experimental workflows.

Table 1. Featured anti-PFKFB1 recombinant antibody products at Creative Biolabs.

Customer Reviews

Excellent

Th**s
Rabbit Anti-PFKFB1 Recombinant Antibody (clone JU53-31) (CAT#: VS3-WK672)

The Rabbit Anti-PFKFB1 Recombinant Antibody worked well in our lab for Western blotting using HEK293 and HeLa cell lysates, detecting a clean band at the expected molecular weight. It also performed reliably in immunofluorescence, staining endogenous PFKFB1 in fixed A549 cells with minimal background. While we haven’t tested it in ELISA yet, the datasheet suggests it’s suitable for detection in non-denaturing assays. The antibody showed good lot-to-lot consistency, though optimization was needed for some tissue homogenates. A solid choice for basic research applications.

08/Feb/2024

Excellent

S**na
Rabbit Anti-PFKFB1 Recombinant Antibody (clone JU53-31) (CAT#: VS3-WK672)

This antibody performed reliably in our WB experiments, detecting clear bands in both mouse liver tissue lysates and cultured HepG2 cells. The signal was specific at the predicted size with minimal nonspecific binding after optimizing blocking conditions. While it worked well for WB, we noticed slightly weaker reactivity in heart tissue samples compared to liver. Overall, it's a dependable option for detecting PFKFB1 in common cell lines and tissues when proper controls are included.

12/Sep/2023

rAb Production

With extensive experience in developing and optimizing recombinant antibodies, we consistently provide premium-quality products backed by rigorous quality control and efficient turnaround times to meet diverse research needs.

Featured Anti-PFKFB1 Recombinant Antibody Production Platforms
Fig.1 Milligram-scale recombinant antibody production.

Fig.2 Gram-scale recombinant antibody production.

rAb Modalities

At Creative Biolabs, we specialize in delivering premium recombinant antibody solutions with cutting-edge engineering capabilities. Our comprehensive portfolio features diverse antibody formats developed through advanced molecular design techniques, supported by fully customizable services to address unique research requirements.

Fig.3 Full Length Anti-PFKFB1 Recombinant Antibody Production and Modalities.

For further details about PFKFB1 or technical assistance, please don't hesitate to contact us by phone or email. Our expert team is readily available to provide guidance and solutions for your experimental needs, helping you overcome challenges and achieve optimal research outcomes.